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The human intestines contain a complex network of trillions of bacteria, approximating 10 11 cells/g of content in the large intestine. Approximately 15,000-36,000 species are estimated to be present in the gastrointestinal (GI) tract 1. 60% of the dry mass of feces consists of bacteria. These bacteria together are called the microbiota and the main part of them is resident in the colon or large intestine. 

The gut microbiota can be classified into 3 domains based on molecular phylogeny (ie, 16S ribosomal ribonucleic acid (rRNA) sequence similarities and differences): Eukarya, Bacteria, and Archaea. Recall that Eukarya consists of organisms with cells that contain complex structures enclosed within membranes, most notably the nucleus. Bacteria are the predominant members of the gut microbiota. The sequencing of 16S rRNA genes from amplified bacterial nucleic acids extracted from fecal material or mucosal samples using high-throughput techniques has facilitated identification and classification of bacteria in the gut. Even if the human intestinal microbiome is one of the most densely populated microbial ecosystems in nature, sequence-based analysis demonstrated that it is characterized by a peculiarly low phylogenetic diversity. Out of the 70 phyla described to date, only 6–10 of bacterial phyla are represented in the gut microbiota: Acidobacteria, Actinobacteria, Bacteroidetes, Firmicutes, Fusobacteria, Lentisphaerae, Proteobacteria, candidate division TM7, Verrucomicrobia and Deniococcus-Thermus., Bacteroidetes and Firmicutes, dominate, accounting for >90% of all phylotypes, whereas a single hydrogen-consuming methanogen, Methanobrevibacter smithii, dominates the Archaea domain 2.
At least half of these organisms cannot be cultured but no one discounts the importance of these elusive microbes. In this vast community of gut bacteria, anaerobes outnumber aerobes by estimates of 100–1000 anaerobes to one aerobe. The mechanisms accounting for composition of the gut flora and how it is assembled are incompletely understood. However, it is clear that, at birth, humans become colonized with facultative aerobes including streptococci and Escherichia coli but, at the critical juncture of weaning, there is a dramatic shift in the gut flora with obligate anaerobes, particularly Bacteroides and Firmicutes species, becoming preeminent 3.

The microbiota in the GI tract in mammals work as an organ and it seems that the relationship between the microbiota and its host is not only commensal but also seems to be a symbiotic relationship.  So the microbiota act in a bigger picture which is called the microbiome. The microbiome is the totality of microbes, their genetic elements (genomes), and environmental interactions in a particular environment. The term "microbiome" was coined by Joshua Lederberg, who argued that microorganisms inhabiting the human body should be included as part of the human genome, because of their influence on human physiology 4. 

In this thesis a number of functions in which the microbiome could play a function will be highlighted. The methods researchers have used will be explained to give the reader more insight in how the microbiome could function.

In the first part of my thesis experiments will be listed to elucidate the role of the microbiome in nutrient uptake. Nutrients pass along the GI and the gut microbiota are able to ferment unused energy substrates in which the host is unable to digest them. The gut microbiome provides here a more efficient way of dealing with the energy that is available. A model is proposed by Martens et al. in how bacteria are able to convert indigestible starches into absorbable molecules 5.
Molecular analysis shows that there is an evolutionary symbiosis between the host and the gut microbiota. Lot of genes are found in the microbiome that are involved in the degradation of starches that can not be degraded by the host itself6.

Because the microbiome plays an important role in nutrient uptake it is also proposed that perturbations in the gut microbiota lead to pathologies. Therefore it is said that the gut microbiome could play a role in obesity 7-12.
Studies on genetically obese mouse and molecular phylogenetic analysis of obese patients learned that the composition of the microbiota is of importance 7, 9, 11.  
Also molecular studies on the host learned that the microbiome has a function for the storage of fats. Genes that are important for the production and storage of fat are more transcribed in mice with a microbiome compared with germ free mice 12.

Not only for obesity there seems to be a relation with the gut microbiome, but also in other pathologies such as Irritable Bowel Syndrome (IBS) and Ulcerative Colitis (UC) 13. These types of correlative observations raise the question of whether the microbiota have a causative role in disease, or whether dysbiosis is a by-product of the disease. For several diseases, recent work shows the answer to be that the microbiota do contribute to disease. Again molecular analysis of the microbiome and studies on transgenic rats reveal an important role for the onset of those diseases 13, 14.

To predict the role of the microbiome in immunity, again studies were done on conventional, germ free and gnotobiotic mice15, 16. Here susceptibility for an enteric pathogen was tested after treatment with antibiotics to see whether the microbiome had protective functions. Furthermore there seems to be immunological, developmental and morphological differences between conventional and germ free animals 17, 18.





















Gut microbiota and nutrient uptake

The gut microflora has several functions. One of these is regulation of the nutrient absorption in the large intestine. 
The stomach and small intestine are responsible for most energy harvest in humans. About 85% of the carbohydrates and 66-95% of the proteins and all fats are absorbed before entering the large intestine. The most part of the microbiota lives in the large intestine. About 10-30% of the total harvested energy is done by the microbes in the large intestine by fermenting indigestible carbohydrates. Without the activity of the colonic microbiota this energy would be lost via the stool, because the large intestine has limited digestive capacity 20.

The gut microbiota deliver metabolic tools which are not encoded by the genome of the host. One such tool is the ability to ferment otherwise indigestible complex glycans to products such as short-chain fatty acids (SCFA) which can be absorbed by the host. This process could render 10-30% of the daily caloric intake depending upon the diet 5.

Martens et al 5, proposed a model in which microbes out of the phylum Bacteriodes were able to degrade polysaccharides unable for the host to degrade. Polysaccharides such as plant cell storage glycans, starches, fructans, and plant cell wall glycans.
Through studies on starch degradation with Bacteroides thetaiotaomicron, a prominent human gut Bacteroidete able to catabolize dietary glycans,
researchers discovered a cell envelope-associated multiprotein system, which they named Sus (Starch utilization system). This system enables the bacterium to bind and process carbohydrates unable to be digested by the host. Microbial genome sequencing projects reveal that homologues of this Sus system are highly presented in the genome of other saccharolytic Bacteriodes 5.

The model of the Sus system contains eight adjacent genes, susRABCDEFG which lie in the Polysaccharide Utilization Locus (PUL). They encode for proteins that are responsible for the transit of glycans through the polysaccharide capsular layer and processing these glycans to monomerized molecules. SusCDEFG localize to the outer membrane. SusC is a protein that belongs to a group of outer membrane-spanning β-barrel proteins that transport solutes and macromolecules. SusDEFG are predicted lipoproteins which are exposed to the external environment. SusA and SusB remain in the periplasm, whereas SusR contains a single internal transmembrane region that allows spanning the cytoplasmic membrane extending domains into both the periplasm and cytoplasm (see figure 1). The process of starch utilization occurs in seven steps. In the first step, glycans transit through the surface capsular layer. In the second step, glycans are bound by outer membrane associated proteins such as SusD, which makes direct contact with starch based on the three-dimensional structure of its helices (see fig 1).






Fig 1.  Functional model of the glycan processing based on the eight-gene B. thetaiotaomicron starch utilization system(Sus) with insets upper left, quick-freeze, deep-etch scanning electron micrograph of the capsule, showing its complex network of polysaccharides. And upper left shows SusD, a starch binding protein, binding to β-cyclodextrin, a cyclic oligosaccharide that mimics the three-dimensional structure of starch. The arc of aromatic residues binding β-cyclodextrin is highlighted in yellow sticks, with the close-up view on the right displaying dashed lines for important hydrogen-bonding interactions. A single Ca2+ ion bound by SusD is shown as an orange sphere 5. (From: Martens et al. 2009)









The nutrient uptake depends on the composition of the gut microbiome. This is the case in mice but it remains uncertain if this also accounts for humans. An alteration in the composition of the gut microbiome could also lead to a different gut metagenome with altered functions in the nutrient metabolism. Jumpertz et al. 7 placed humans in cohort study and tested whether there were changes in the bacterial community structure when the nutrient load was altered. They took lean and obese individuals and looked if the composition of their microbiota correlated with the efficiency of dietary energy harvest. They tracked changes of the microbial community by pyrosequencing bacterial 16S rDNA present in the feces of 12 lean and 9 obese individuals and analyzed the energy harvest by measuring ingested and stool calories with the use of bomb calorimetry.
They observed that alteration of the nutrient load leads to rapid changes in the composition of the gut microbiome, and these changes were directly correlated with stool energy loss. In lean individuals there was a 20% increase in Firmicutes and a comparable decrease of 20% in Bacteriodetes that was associated with an increased energy harvest of 150 kcal/day. A high degree of overfeeding in lean individuals was accompanied by a greater fractional decrease in stool energy loss7.


By sequencing the microbial genomes and identifying genes that are used in metabolic pathways, insight can be gained into how the gut microbiome helps in the sequestering of nutrients by the host. The human distal gut microbiome contains by estimate more than 100 times more genes than our human genome.

By analysis of COGs (Clusters of Orthologous Groups) which are genes that have evolutionary relationship and KEGGS (Kyoto Encyclopedia of Genes and Genomes, version 37) pathways that analyzes genes in known metabolic pathways, genes could be classified in functional related groups and identified. COG analyses demonstrated enrichment of key genes involved in generating acetate, butyrate, lactate, and succinate in the gut metagenome compared with all microbial genomes in the COG database 6. 

Further COG analysis shows that the metagenome is enriched with genes that are essential for the synthesis of vitamins and essential amino acids. Genes were found involved in the 2-methyl-d-erythritol 4-phosphate (MEP) pathway used for biosynthesis of deoxyxylulose 5-phosphate (DXP), and isoprenteryl and pyrophosphate (iPP). DXP is a precursor in the biosynthesis of vitamins essential for human health, including B1 (thiamine) and B6 (pyridoxal form) and isopenteryl pyrophosphate (IPP). IPP is an isoprenoid that can give rise to at least 25,000 derivatives including cartenoids, archeal membrane lipids and cholesterol6.


When the human genome was compared with that of an average of the sequenced microbial genomes, the microbiome was significantly enriched with genes involved in the metabolism of glycans, amino acids, xenobiotics and methanogenesis. 
The plant polysaccharides that we commonly consume are rich in xylan-, pectin-, and arabinose-containing carbohydrate structures. The human genome lacks most of the genes encoding enzymes required for degrading these glycans. However, the distal gut microbiome provides us with this capacity. The human gut microbiome is enriched in genes involved in starch and sucrose metabolism plus the metabolism of glucose, galactose, fructose, arabinose, mannose, and xylose.
At least 81 different glycoside hydrolase families are represented in the microbiome, many of which are not present in the human “glycobiome” 6.






Gut microbiota and obesity. 

The gut microbiome exerts a strong effect on nutrient uptake, but it may also influence pathologies related to food uptake. One of them is the onset and development of obesity.
The gut microbiome could have influence on obesity in four ways 8:
1 Intestinal microorganisms could contribute to obesity by enlarging the energy harvest out of our diet. This is mainly done by the breakdown of indigestible fibers in the large intestine. These fibers can be broken down to short molecules that could be taken up by the body as have been shown in the previous chapter. This is called the energy harvest hypothesis
2 Microbiota and/or their metabolites can regulate gut physiology, especially gut transit. This means that the flow of potentially digestible compounds from the small intestine to the large intestine could be altered thereby influencing the energy uptake from the diet. 
3 Microbiota and their metabolites could have an effect on obesity by acting as signals on the host pathways that regulate energy intake and/ or fat deposition.
4 Intestinal microorganisms could intensify the energy expenditure by placing an extra energetic burden on the host. The gut microbiota induce decay of gut tissue so new gut tissue has to be synthesized. Other factors are inflammation, triggering of host immune system or by other effects that increases the loss of energy(Fig 2).






Furthermore, in obesity the ratio between the two main phyla Firmicutes and Bacteroidetes seems to be important. These phyla determine over 90% of all phylotypes in mice, just as they do in humans22.
In normal healthy mice the relative abundance of Bacteriodes is higher than that of the phylum Firmicutes. However, the relative abundance of the Bacteroidetes in obese mice was reduced by about 50% whereas the relative abundance of Firmicutes was increased
This difference was not attributable to differences in food consumption11.

In humans the relationships obesity and the microbiome are less clear. Whereas in one study the Firmicutes to Bacteroides ratio in obese people was increased9, in other studies such a relationship was not observed 8. 

Germ free (GF) mice weigh less than mice with normal gut microbiota given from birth (conV-R), mice. It seems that conV-R mice contain 42% more body fat12. The mice were given a normal rodent chow diet (57%carbohydrates,5% fat) and the consumption by GF mice was 27% less than that of conV-R mice. Mice that were grown up in a germ free environment for 8 -10 weeks but inoculated after 14 days with intestinal samples of the conV-R mice had an even higher increase of body fat.

The microbiome stimulates deposition of triglycerides in adipocytes, cells which are specialized in the storage of fat, through suppression of intestinal expression of circulating Lipoprotein Lipase (LPL) inhibitor. LPL is a key regulator of fatty acid release from triglyceride-rich lipoproteins in muscle, heart, and fat. Increased adipocyte LPL activity leads to increased cellular uptake of fatty acids and adipocyte triglyceride accumulation. By looking at the transcription of other biomarkers for fatty acid biosynthetic pathways and pathways for the storage of fat in cells, no difference between GF mice and conV-R mice was observed but when looking at LPL, a large difference was observed between GF and conV-R mice. The expression of Fasting-induced adipocyte factor (Fiaf), an inhibitor of LPL, was significantly different in the intestine of GF and conV-R mice 12.  The microbiome seems to be responsible for this enhanced activity of LPL in conV-R mice because the transcription of the inhibitor fiaf is strongly induced in GF mice, but not in normal and conV-R mice. Also transcription factors involved in the fatty acid synthesis ChREBP and SREBP-1, in the liver were elevated in conventionalized mice compared with GF mice.  











Fig 3. Schematic representation of the influence of the microbiota in the gut on the triglyceride storage in adipocytes. (From Backhed et al. 2004)







Gut microbiota and other pathologies

Diseases like Irritable Bowel Syndrome (IBS) and Ulcerative Colitis (UC) are two disorders of the GI tract which share common symptoms such as pain and alteration of the bowel habits. Although the exact causes of these diseases are still not clear, they must be multifactorial in origin. Host genetics, environmental factors, and unregulated immune responses are involved. Today most studies suggest that the gut microbiome is an important factor in the pathogenesis in diseases such as UC and IBS.

One of these studies on the involvement of the microbiome in UC and IBS was done with HLA-B27 transgenic rats. HLA-B27 rats were used as animal model for studying human inflammatory disorders. When kept under germ free conditions they do not develop inflammation in the small or large bowels. When germ free HLA-B27 rats were recolonized with normal gut microbiota they developed gut inflammation 14.

Noor et al.13, used a molecular approach to identify differences of gut microbiota composition of human individuals with UC or IBS and compared that with normal healthy individuals as a control. Their fecal microbiota was analyzed with PCR- Denaturing Gradient Gel Electrophoresis (DGGE) using universal and Bacteriodes specific primers. The differentiated bands were then identified by sequencing the V3 region of the 16S rRNA genes. The number of bacterial species seemed much lower in UC and IBS patients than in healthy individuals. Another result of this study is that there was larger variability of predominant bacteria in UC and IBS patients indicating that there are more perturbations in unhealthy individuals and healthy individuals have more stable gut microbial communities.
DNA sequencing of discriminating bands between healthy and unhealthy individuals suggest that the presence of Bacteroides vulgatus, B. ovatus, B. uniformis, and Parabacteroides sp. in healthy volunteers distinguishes them from IBS and UC patients. DGGE profiles of Bacteroides species revealed a decrease of Bacteroides community in UC relative to IBS and controls 13. These findings indicate that the use of probiotics could be helpful in patients with UC and IBS. Probiotics are live microorganisms that when administered in adequate amounts confer a health benefit on the host. Probiotics are not effective in each individual for as yet unclear reasons. The effectiveness may be improved when bacterial species that are of importance for the health of a particular patient can be identified. 

Another therapy that could work in the recovery of ill people is the use of bacteriotherapy. The hypothesis behind fecal bacteriotherapy is that people suffer from a dysbiosis in the gut. An altered composition of the gut microflora clears the path for pathogens in the gut. In normal healthy individuals the complex network of the microbes is stable and difficult to alter because there is mutualism between the microbial species. That’s why it is difficult for a strange pathogenic enterobacterium to accommodate in the gut. Unhealthy people with an altered community composition of gut microbes have lost this strong homeostasis where species not only compete but also benefit from each other. When this is the case it is thought that when the normal balance is restored in gut microbial composition the pathogen is no longer able to maintain itself and is replaced by commensal bacteria through competition. Another theory is that the normal resident bacteria in the gut produce antimicrobial agents (bacteriocins) that will eradicate pathogenic bacteria such as C. difficile. To do this unhealthy people are treated with feces from healthy individuals. This procedure is quit simple and has proven to work in a lot of studies 24.  


The role of the gut microbiota in immunity

The microbiota in the G-I tract consists of hundreds of phylotypes and from the five phyla which are represented in the intestine the main phyla in the gut are the firmicutes and the Cytophaga-Flavobacterium-Bacteroidetes(CFB). More than 90% of the commensal bacteria in the GI tract belong to these two phyla. It seems that at the level of the phyla there is little variation between individuals of the same species. Even between species, like humans and mice, there is little variation on the phylum level. The variation exists in the species or strains within these phyla.
Changes in the composition of the gut microbiome, could lead to susceptibility for diseases. The immune system ‘learns’ how to react on the microbial species given since birth. When there is a drastic shift in microbial species, induced by for instance antibiotic treatment, the immune system is not able to anticipate on that and that may clear the path for pathogens or auto-immune diseases. 

Perturbations in the microbiota could lead to various diseases. After treatment with antibiotics it is often seen that people contract a Clostridium difficile infection. This supports the hypothesis that perturbations could lead to the onset of a disease. 

To study this experimentally, conventional mice were treated with a broad spectrum antibiotic and an antibiotic with a gram-positive spectrum. These were streptomycin and vancomycin respectively. Both antibiotics are used in clinical practice for a wide variety of infections. Subsequently the mice were inoculated with the pathogen Salmonella typhimurium. This is a pathogen known to be unable to colonize the gut in normal, healthy mice. However, after treatment with the antibiotics, S. typhimurium was able to colonize the gut, further perturbed the intestinal microbiome and induced intestinal pathology. Not only reducing the numbers of commensal bacteria in the microbiome could change the susceptibility of the mice gut, also a change in the composition of the intestinal microbes was sufficient to make the mice more susceptible to S. typhimurium indicating that different subsets of the intestinal microbiota could have protective roles or enhance susceptibility to infections 15. 

These findings suggest that the microbial ecosystem, once it is formed, efficiently prevents invasion by foreign species. This is called ‘colonization resistance’ (CR). It remains unclear what the molecular bases is of CR but when the gut microbiome is disturbed or absent (i.e. germ free or after antibiotic treatment) the infection risk increases drastically.

Another way to investigate the role of the gut microbiota in immunity is to create artificial communities in so called gnotobiotic sytems. By infecting a germ free organism with a limited number of known microbes, this organism can be used in experiments that study the influence of this limited set of micro organisms. Other advantages are that gnotobiotic mice are much easier to maintain and that
the gut mucosal immune system and innate immune system are partially normalized when compared to germfree mice.

Stecher et al.16 constructed gnotobiotic mice by colonizing germ free mice with Altered Scheadler Flora (ASF). ASF is a mixture of eight different strains that are normally found in the gut of rodents. Innoculated mice are designated as ‘LCM mice’ which stands for standardized low complex type of gut microbiota16. The LCM mice are susceptible to pathogens like S. typhimurium comparable to conventional mice that were treated with antibiotics. Normal conventional mice with a normally developed gut microbiota used as a control were not invaded by to S. typhimurium indicating that a low complex type of microbiota is not sufficient for protection against pathogens.
Colonization resistance is transferred from conventional mice to LCM mice in a period of 21 days when the mice are put together in one cage.  Abundance of some species in the gut flora could indicate the susceptibility for specific pathogens, thus individual differences in the composition of the gut microbiome could explain why one individual can be invaded by a certain enteric pathogen while others are not. This also accounts for the differences of effectiveness of probiotics among individuals. In these studies a screening model for humans with some bacterial species as indicator species for susceptibility for pathogens was proposed 16.  

Immunologic and developmental differences exist between germ free mice and conventional mice. Germ free animals for instance show extensive defects in the development of gut-associated lymphoid tissues and in antibody production. They have fewer and smaller Peyer’s pathes and Mesenteric lymph nodes compared to animals with a conventional gut microbiota which were grown under specific pathogen free (SPF) conditions. These defect structures form normally after introduction of conventional gut flora in germ free animals, suggesting a dynamic relationship between the immune system and the gut microbiome 17.
 






Microbiota and their role in the development of behavior 

To elucidate the role of gut microbiome in for instance nutrient uptake it was noticed that germ free animals and SPF conventional mice not only differed in nutrient uptake also differences in behavior were observed. Upon these observations studies were initiated to unravel the role of the gut microbiome in behavior. 
Recent studies in animal models revealed a relation between the gut microbiota and the Central Nervous System (CNS). This so-called brain-gut axis seems to be important throughout life in the development of the organism. The relation between the gut microbiome and brain biochemistry, including behavior, seems implausible. However, patients with an altered mental status due to hepatic encephalopathy are treated on a routine basis with laxatives and oral antibiotics. Other clinical studies reveal that people with autism have an altered gut microbiota composition. Some reports describe that certain people developed a psychosis after a treatment with antibiotics. Another indication was that female patients that developed depression had a direct link to an increased fermentation of carbohydrates. This implicates changes in the gut microbiome or a change in the metabolic activity of the gut microbiota 19. 

Evidence that microbiota are linked to brain chemistry and behavior mostly comes from studies with animals. Mice inoculated with the intestinal pathogen Campylobacter jejuni in their GI tract showed after inoculation anxiety-like behavior already a few hours after innoculation. This abnormal behavior was displayed before there was any significant immune response, indicating that this behavior was not a consequence of cytokine-induced reactions. Alterations of brain chemistry and a specific activation pattern in multiple brain regions that were related to anxiety-like behavior were detected. This seems to indicate that the neural system can detect an acute change in the gut implicating a relation between the gut microbiome and the neural system 19. 

Inoculation of mice with Helicobacter pylori affected gastric physiology in terms of delayed gastric emptying and altered neural physiology, with again a change in behavior. This H. pylori infection leads to altered feeding behavior characterized by frequent feeding bouts but with less food consumed per feeding activity than controls. This is reminiscent of early satiety in patients with functional dyspepsia. Again there were changes in neural biochemistry of these mice. Interestingly, altered behavior and biochemical abnormalities persisted for at least two months postbacterial eradication, suggesting that changes induced by chronic infections in the CNS may be long lasting or permanent 19.


Another experimental approach to link the gut microbiome and the CNS including behavior is the use of germ free mice and SPF mice. Germ free mice subjected to standard behavioral tests such as elevated plus maze, open field and light/dark preference tests show different behavior compared with SPF mice. Germ free mice show increased motor activity or exploratory behavior and lower anxiety-like behavior compared with SPF mice. When looked at the gene expression by means of in situ hybridization technique of mRNA’s in different parts of the brain, differences in the biochemistry were found. There were differences in the expression of neutrophins such as nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF). Neutrophins are a group of growth factors that work in the CNS. Their expression was higher in the brains of SPF mice compared with that of germ free mice. This could explain differences in behavior between germ free animals and conventional mice. Another result was that when germ free mice were conventionalized early in life expression patterns of genes involved in the biochemistry were the same as in normal SPF mice 25.

In other experiments the stable gut microbiota in adult healthy mice was perturbed creating gut dysbiosis by oral administration of non-absorbable antibiotics. A combination of neomycin, bacitracin and pimaricin induced changes in colonic microbiota composition in SPF mice with a marked increase in Furmicutes, mainly Lactobacilli spp. and a decrease in γ-proteobacteria. This was accompanied by an increase of exploratory behavior or motor activity and altered biochemistry 19. These changes were not observed when the antibiotics were administered in the blood stream.









It seems that the gut microbiome is a complex organ that forms a super organism together with the host. The influence of the hundreds of species in unimaginably numbers seems to be much greater than we had ever thought. Their involvement on the development and functioning of so many features of the host signifies the importance of the microbiome. Functions such as food uptake, development of a well functioning immune system and even brain chemistry seems to be controlled by the gut microbiome. 

The gut microbiota seems to have co-evolved for a long time with its host. This is expressed in the mutual benefits that both the host and the microbial species have from each other. One mutual benefit is the degradation of carbohydrates by the microbiota that can not be ingested by the host itself. The gut microbiome seem to be enriched with genes specialized in the utilization of for the host indigestible plant polysaccharides and mechanisms like the Sus system that convert those polysaccharides into SCFA’s that can be utilized by the host.

Sometimes the gut microbiome does its work too efficiently and pathologies in the nutrient uptake such as obesity develop. Based on 16S rDNA sequencing, a shift of the gut microbiome composition was observed and using germ free and conventional mice a relation was shown between the production of triglycerides and the storage of fat and the gut microbiome. But there also seem to be factors in the genome of the host influenced by the gut microbiome that will increase the production of fatty acids and storage of fat in adipocytes.

The importance of the gut microbiome seems to be underlined in cases when it goes wrong. In many bowel diseases such as UC and IBS, dysbiosis seem to be one of the main factors of symptoms of the syndrome. Studies on animal models in germ free status or conventional ones and molecular studies on the microbiome learned that there is an alteration of the gut composition of the microbiota and that an unbalanced gut microbiome loses its strength to prevent diseases that involves the gut. Much research remains to be done on all the species of the microbiota to profit on the use of probiotics because it is as yet unclear which species are responsible in creating the unbalance. Bacteriotherapy, however seems to be more helpful in restoring that balance in gut microbiota composition.

To elucidate the role of the gut microbiome in immunity again it is thought that an alteration of the gut microbiome composition clears the path for pathogens or auto immune diseases because the immune system could not function properly. Studies on conventional and gnotobiotic mice treated with antibiotics and then inoculated with enteric bacterial pathogens that wouldn’t otherwise be able to colonize the host were capable in doing so. This indicates that a normal healthy composition of the gut microflora is important for a normally functioning immune system. 

Although the relationship between brain and the gut microbiome seems unlikely, such a relationship is strongly suggested. Studies on animals reveal changes in behavior when the gut microbiota were absent.

There are still problems to elucidate functions such as nutrient uptake, immunology and pathology. The complexity of the composition of the gut microbiome means that a lot of species and strains are still unknown. This could imply that some of those unknown species play a pivotal role in the physiology of the host, which we are still not aware of. Whereas there is methodology for identification by means of sequencing the 16S rRNA, identification itself is not enough. Extensive studies should be done on unknown species to see if their features could play a role in the host physiology. When all species in the microbiome are identified, a complete picture can be made of how the gut microbiota relates to their host.
Another limitation is that it is impossible to make elaborate studies on humans. Animals, in particularly mice seem to be the best in vivo model to study the role of microorganisms in the gut. What is upcoming and perhaps will expand the possibilities to unravel the microbiota’s role in an organism is the use of human cell lines and human cell models. Experimental setups can be made in which epithelial cells could be polarized on a microporous membrane in such a way that they mimic the interior of the body and a lumen of the gut. This in combination with immune cells and gut microbiota a model is made that resembles the in vivo situation. Now interactions with the microbiota in combination with pathogens could be studied. Questions as how does the gut microbiota help the epithelial cells in keeping a good barrier function against pathogens or how does the microbiota stimulate immune cells to eradicate pathogens could now be investigated 26. These models could have advantages that would be prevalent the use instead of using animals. 

Because the molecular techniques are getting better and better, new genes could be identified based on their molecular structure of their gene product. This could be used to screen the genome of the host in search of differences between GF animals and conventional ones. Furthermore more genetically altered animals could be made to unravel the role of the microbiome in putative functions. This clears the path for new developments in the unraveling of functions of the microbiome.  
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